New CIRM CLIN2 and PDEV Funding Opportunities

Advancing Regenerative Medicine at UCLA: New CIRM CLIN2 and PDEV Funding Opportunities

The California Institute for Regenerative Medicine (CIRM) has launched two new funding opportunities—CLIN2 and PDEV—designed to accelerate promising regenerative medicine, gene, and cell therapy programs from discovery through early‑stage clinical development. These programs represent a significant opportunity for UCLA investigators advancing innovative therapies with strong translational and clinical potential. 

To support investigators pursuing these highly competitive awards, the CIRM‑funded UCLA Alpha Clinic offers dedicated grant consultation and end‑to‑end research navigation services tailored specifically to the CLIN2 and PDEV mechanisms.

UCLA Alpha Clinic: Your Strategic Partner for CIRM Funding

The UCLA Alpha Clinic is led by Dr. Noah Federman and Dr. Laurie Shaker‑Irwin, who direct UCLA’s CIRM‑funded efforts in regenerative medicine, gene therapy, and cell therapy clinical research. Together, they oversee a multidisciplinary infrastructure designed to help investigators successfully advance therapies from the laboratory to the clinic. 

The Alpha Clinic works in close partnership with UCLA’s Clinical and Translational Science Institute (CTSI) and the Broad Stem Cell Research Center (BSCRC) to help investigators navigate UCLA’s research ecosystem, align proposals with CIRM priorities, and build competitive, fundable applications.

Comprehensive Support Across the Translational Pipeline

Alpha Clinic consultation services are designed to match the specific scientific, operational, and regulatory needs of CLIN2 and PDEV applicants.

Discovery and Translational Development Support

Investigators in early and mid‑stage development can access resources that support:

• Lead candidate identification and optimization
• Translational planning and milestone development
• Alignment of preclinical data packages with CIRM expectations
• Strategic guidance on readiness for IND‑enabling studies and future clinical testing

Clinical Research and Trial‑Readiness Support

For programs advancing toward or into the clinic, Alpha Clinic resources include:

• Clinical protocol development and trial design
• Regulatory strategy and FDA affairs support
• Research coordination and operational planning
• Statistical analysis, data management, and trial readiness assessment

This integrated approach ensures that scientific innovation is paired with robust operational and regulatory foundations, a key success factor for both CLIN2 and PDEV applications.

Start with a Consultation: Let’s Talk About Your Proposal

Because CLIN2 and PDEV applications require careful alignment of scientific aims, resource needs, and institutional capabilities, the Alpha Clinic begins support with a focused consultation.

Investigators are encouraged to complete the CIRM Funding Opportunity Interest Survey. This brief survey allows the Alpha Clinic team to understand your project’s scope, stage, and anticipated resource needs. Following submission, the Alpha Clinic will contact you and/or your designee directly to schedule a one‑on‑one meeting to discuss:

• Your specific CIRM funding strategy
• Available UCLA and Alpha Clinic resources
• Gaps, risks, and opportunities to strengthen your application

Partner Early to Strengthen Your Application

Early engagement with the UCLA Alpha Clinic allows investigators to:

• Clarify expectations for CLIN2 and PDEV funding mechanisms
• Build realistic, competitive development plans
• Leverage UCLA resources efficiently through CTSI and BSCRC partnerships
• Avoid common regulatory and operational pitfalls

Whether you are advancing a promising lead candidate or preparing for early clinical testing, the UCLA Alpha Clinic is committed to helping investigators translate innovation into impact through successful CIRM funding.

Complete the CIRM Funding Opportunity Interest Survey to begin the conversation and schedule your Alpha Clinic consultation.